Lilly declares second-quarter 2025 dividend The board of directors of Eli Lilly and Company (NYSE:LLY) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding...
Monday, May 5, 2025 BiopharmaWatch Research 1 min read
Key Takeaway: Eli Lilly and Company has announced a dividend of $1.50 per share for the second quarter of 2025. This dividend will be payable on June 10, 2025, to shareholders who are on record as of May 16, 2025. The announcement highlights Lilly's commitment to returning value to its shareholders, although it also includes caution regarding uncertainties in pharmaceutical research and development. The statement underscores the need for investors to be aware of potential risks that could affect expected outcomes.
Price reaction · baseline $823.62 (2025-05-02 close) · 1 other LLY headline(s) in the window, move may be shared
day 0 close
-0.3%
Market Sentiment Analysis
POSITIVE FACTORS
Eli Lilly declared a solid dividend of $1.50 per share.
The dividend reflects confidence in the company's financial health.
Payable to shareholders on June 10, 2025, demonstrating ongoing shareholder returns.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+45%
120-day peak, hindsight
Typical move
2%
average across 15 past catalysts
Lead asset
Dulaglutide
Phase 3 · Type 2 Diabetes Mellitus
Full Press Release Details
INDIANAPOLIS , May 5, 2025 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY ) has declared a dividend for the second quarter of 2025 of $1.50 per share on outstanding common stock.
The dividend is payable on June 10, 2025 , to shareholders of record at the close of business on May 16, 2025 .
Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about expected dividend payments and reflects Lilly's current beliefs and expectations. However, there are significant risks and uncertainties in pharmaceutical research and development, as well as in business development activities and capital allocation strategies related to the company's business and actual results may differ materially due to various factors. For further discussion of risks and uncertainties relevant to Lilly's business that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.